8-K: Gain Therapeutics Files Prospectus for $35.5M ATM Offering

Gain Therapeutics, Inc. filed a prospectus supplement to offer and sell up to $35.5 million of common stock through an at-the-market offering program.

Summary

• Gain Therapeutics, Inc. (the Company) filed a prospectus supplement on November 28, 2025, in connection with its at-the-market (ATM) offering program.
• The program allows for the offer and sale of up to $35,530,980.56 of the Company's common stock.
• Sales will be made from time to time through Oppenheimer & Co. Inc. as the sales agent.
• This offering is pursuant to an existing Equity Distribution Agreement dated September 6, 2024.
• As of November 28, 2025, the Company has already sold an aggregate of $14,469,019.44 of common stock under the same Distribution Agreement.
• The offer and sale of additional common stock will be made under a shelf registration statement on Form S-3 (File No. 333-287622), which became effective on November 26, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the offering provides crucial financial flexibility and access to capital, which is positive for a development-stage company, it also introduces potential dilution for existing shareholders, which is a negative factor.

Positives

• The ATM offering provides the Company with a flexible and efficient mechanism to raise capital as needed, without the immediate pressure of a large, fixed-price offering.
• Access to capital can support ongoing operations, research and development, and strategic initiatives.

Negatives

• The sale of additional common stock will result in dilution for existing shareholders, potentially reducing the value of their current holdings.
• The timing and pricing of share sales are subject to market conditions, which could impact the average price realized by the Company.

Risks

• Dilution of existing shareholders' equity and voting power due to the issuance of new common stock.
• The actual amount of capital raised and the average price per share will depend on market conditions and demand for the Company's stock during the offering period.
• The Company's status as an 'emerging growth company' may impact its compliance requirements and investor perception.

Future Outlook

The Company intends to continue offering and selling common stock from time to time through its at-the-market program, leveraging the newly filed prospectus supplement to access up to $35.5 million in additional capital.

Management Comments

• The report was signed by Gene Mack, Chief Executive Officer of Gain Therapeutics, Inc., on November 28, 2025.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital-raising tool, particularly for biotechnology and pharmaceutical companies like Gain Therapeutics, which often require ongoing funding for research, development, and clinical trials. This method allows companies to raise capital incrementally, adapting to market conditions and specific funding needs without the significant upfront costs and market disruption associated with traditional underwritten offerings.

Comparison to Industry Standards

• ATM offerings are a standard financing mechanism widely utilized across various industries, especially in sectors with high capital expenditure requirements such as biotechnology.
• This approach is comparable to similar programs adopted by numerous small to mid-cap public companies seeking efficient access to equity capital.
• The use of Oppenheimer & Co. Inc. as a sales agent is consistent with industry practices for such offerings, where investment banks facilitate the sale of shares into the open market.

Stakeholder Impact

• Shareholders: Potential for dilution of existing shareholdings as new common stock is issued and sold into the market.
• Company: Enhanced financial flexibility and access to capital to fund operations, research, and development initiatives.

Next Steps

• The Company will continue to offer and sell common stock under the at-the-market program as market conditions and capital needs dictate.
• Oppenheimer & Co. Inc. will act as the sales agent for these transactions.

Key Dates

Keywords

Gain Therapeutics, GANX, ATM offering, equity distribution, common stock, prospectus supplement, capital raise, dilution, SEC filing, Form 8-K